A start-up is giving its employees a new Tesla car, which is expected to cost $35-thousand each. » Read More
CNBC's Dominic Chu; Jim Iuorio, Managing Director at TJM Institutional Services; and David Seaburg, Managing Director and Head of Sales & Trading at Cowen & Company, discuss top fear trades on this Friday the 13th.
MIT researchers are developing a device that could one day help patch internal wounds, deliver medicine or remove accidentally swallowed objects from the stomach.
Dr. Andre Choulika, Cellectis CEO, discusses how gene editing could lead to a new way to fight cancer.
Discussing the impact of biotech deals on the sector overall, and whether Sanofi's offer for Medivation will pass, with Michael King, JMP Securities, and Les Funtleyder, E Squared Capital.
Sam Isaly, OrbiMed Advisors founder, discusses health care industry stock picks.
Martin Shkreli, former CEO of Turing Pharmaceuticals, will appear in at the U.S. District Court in Brooklyn Tuesday following December's seven-count indictment, reports CNBC's Meg Tirrell.
GlaxoSmithKline CEO Andrew Whitty thinks his company's success has been a product of being patient and investing in innovation.
Sarepta Therapeutics shares soared Monday after the stock was upgraded to "outperform" at Oppenheimer.
Jesper Brandgaard, CFO of Novo Nordisk, discusses the pharmaceutical company's earnings results and the impact of the declining dollar.
Analysts expected Gilead to report earnings of about $3.15 a share on $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.
April 28- AbbVie Inc said it would buy privately held oncology company Stemcentrx in a deal valued at $5.8 billion to expand its portfolio of drugs to treat cancer. AbbVie also lowered it full-year adjusted profit forecast to $4.62- $4.82 per share from $4.90- $5.10. AbbVie had bought Pharmacyclics Inc for about $21 billion in March last year, giving it access to...
Potential market cap swings in biotech with CNBC contributor Dan Nathan.
Sarepta was down sharply a day after an FDA advisory committee voted against recommending the company's Duchenne muscular dystrophy drug.
Discussing the play on Sarepta Therapeutics as its Duchenne muscular dystrophy drug sees pressure from FDA, with the FMHR traders.
CNBC's Meg Tirrell reports on the possibility of Perrigo CEO Joseph Papa heading over to Valeant, as well as biotech firm Interxon feeling some pressure after the release of a report calling it 'the new Theranos.'
CAMBRIDGE, England, April 22- AstraZeneca, working with genome pioneer Craig Venter, is launching a massive gene hunt in the most comprehensive bet yet by a pharmaceutical firm on the potential of genetic variations to unlock routes to new medicines. AstraZeneca will work with Venter's U.S. company Human Longevity Inc, which will sequence the genomes, including...
Robert Greifeld, Nasdaq CEO, discusses bank earnings, the IPO market, and more at the eMerge Americas conference.
Federal regulators are investigating blood-testing start-up Theranos over whether it misled investors.
Adam Parker, Morgan Stanley chief U.S. equity strategist, thinks biotech and pharma look attractive, in discussing his market forecast.
Following his announcement to donate $250 million for cancer research, Sean Parker joined CNBC to discuss his initiative.